Economic evaluation for ophthalmologists

Ophthalmic Epidemiology

Volumn 13, Issue 6, 2006, Pages 393-401

  Kuper, Hannah ^a   Jofre Bonet, Mireia ^a,b   Gilbert, Clare ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Cost benefit analysis; Cost effectiveness; Cost utility; Economic evaluation; Healthcare utilization; Ophthalmology; Quality adjusted life years

Indexed keywords

ACICLOVIR; BENZOPORPHYRIN DERIVATIVE; BRINZOLAMIDE; DORZOLAMIDE;

CONFIDENCE INTERVAL; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; ECONOMIC EVALUATION; EYE CARE; EYE DISEASE; FUNDING; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HERPES SIMPLEX VIRUS; HUMAN; INTERVENTION STUDY; INTRAOCULAR HYPERTENSION; KERATITIS; KNOWLEDGE; LOWEST INCOME GROUP; MONEY; OPEN ANGLE GLAUCOMA; OPHTHALMOLOGY; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; READING; RESOURCE ALLOCATION; REVIEW; SENSITIVITY ANALYSIS; SUBRETINAL NEOVASCULARIZATION;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; OPHTHALMOLOGY; PHYSICIANS;

EID: 33845792371     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.1080/09286580600760539     Document Type: Review

References (26)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull WHO. 2004;82:844-851.
2. Williams A. Health and Economics. Houndmills: Macmillan, 1987.
3. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd ed. Oxford: Oxford University Press, 1997.
4. Frick KD, Foster A, Bah M, Faal H. Analysis of costs and benefits of the Gambian Eye Care Program. Arch Ophthalmol. 2005;123(2):239-243.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
6. Muralikrishnan R, Venkatesh R, Prajna NV, Frick KD. Economic cost of cataract surgery procedures in an established eye care centre in Southern India. Ophthalmic Epidemiol. 2004;11(5):369-380.
7. Jampel HD, Schwartz GF, Robin AL, et al. Patient preferences for eye drop characteristics: a willingness-to-pay analysis. Arch Ophthalmol. 2003;121(4):540-546.
8. Brown M. Utility analysis tells all. Br J Ophthalmol. 2005;89(10):1233.
9. Gupta SK, Viswanath K, Thulasiraj RD, et al. The development of the Indian Vision Function Questionnaire (IND-VFQ): field testing and psychometric evaluation. Br J Ophthalmol. 2005;89(10):621-627.
10. EQ-5D E. http://www.euroqol.org/web/, 2006.
11. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473-511.
12. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;5(4):559-575.
13. Cairns J. Discounting in economic evaluation. In: Drummond M, McGuire A. Economic evaluation in health care ed. Oxford: Oxford University Press, 2001;236-255.
14. Rouland JF, Le Pen C, Gouveia Pinto C, Berto P, Berdeaux G. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries. Pharmacoeconomics. 2003;21(3):201-213.
15. Florio M. The economic rate of return of infrastructures and regional policy in the European Union. Ann Public Coop Econ. 1997;68(1):39-64.
16. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making. 1990;10(3):212-214.
17. James M, Turner DA, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. Br Med J. 2000;320(7250):1627-1631.
18. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146(4):473-481.
19. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-1641.
20. Busbee BG, Brown GC, Brown MM. Cost-effectiveness of ocular interventions. Curr Opin Ophthalmol. 2003;14(3):132-138.
21. Kuntz K, Weinstein M. Modelling in economic evaluation. In: Drummond M, McGuire A. Economic evaluation in health care ed. Oxford: Oxford University Press, 2001;141-171.
22. Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol. 2003;121:108-112.
23. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-338.
24. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age-related macular degeneration: the UK case. Br J Ophthalmol. 2004;88(9):1107-1112.
25. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A. Economic evaluation in health care ed. Oxford: Oxford University Press, 2001;172-214.
26. Marseille E. Cost-effectiveness of cataract surgery in a public health eye care programme in Nepal. Bull WHO. 1996;74(3):319-324.